Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR1400 in Essential Hypertension
NCT07373613Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BR1400-1 in essential hypertension, sponsored by Boryung. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
BR1400-1
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07373613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373613.